ViferaXS raises $12.0M Series A (Germany, Sep 2026)
Reach the investors backing rounds like this
Backed by SPRIND, Huma · verified emails and LinkedIn on Datapile
ViferaXS secures up to €12M for leukemia trial - European Biotechnology Magazine
ViferaXS is a German biotech company developing peptide-based cancer immunotherapies. They are advancing a treatment for chronic lymphocytic leukemia (CLL) into a Phase 2 trial. This funding will support testing the therapy's efficacy in a randomized study.
ViferaXS secures up to €12M for leukemia trial European Biotechnology Magazine
| Nov 04, 2026 | Conlio | $6.9M | — | Germany |
| Nov 04, 2026 | Return | $903.0M | Debt | Germany |
| Nov 03, 2026 | Quint | $9.9M | — | Germany |
| Nov 03, 2026 | Quint Computing | $9.1M | — | Germany |
15,819 investors back startups in Germany
You just read who funded ViferaXS. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.